Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 955 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06891833RecruitingPhase 2/Phase 3
New drug combo for HER2-positive breast cancer before surgery
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Bengbu, AnhuiAges 18–75 - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06830889RecruitingPhase 3
BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06706557Recruiting
Studying tumor DNA in HER2-low advanced breast cancer
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
Milan, MIAges 18 years+ - NCT06693024Recruiting
Neratinib after standard therapy for HER2-positive early breast cancer
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Beijing, Beijing MunicipalityAges Any age - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
San Francisco, CaliforniaAges 18 years+ - NCT06534125Recruiting
Acupuncture to prevent joint pain from hormone therapy in Black women
This study tests whether acupuncture can prevent joint pain caused by a common hormone therapy pill (aromatase inhibitor) in Black women who have finished treatment for early-stage breast cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06450873RecruitingPhase 2
Turkey tail mushroom before breast cancer surgery
This trial tests whether taking a turkey tail mushroom supplement before breast cancer surgery can help the immune system fight the cancer. It is for post-menopausal women with a common type of breast cancer (ER-positive, HER2-negative) that is growing at a moderate or faster rate (Ki-67 score of 10% or more).
Scottsdale, ArizonaAges 18 years+ - NCT06217185RecruitingPhase 4
Pyrotinib and trastuzumab with chemo for HER2+ advanced breast cancer
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Shijiazhuang, HebeiAges 18–70 - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT06330012Recruiting
Understanding resistance to T-Dxd in HER2+ breast cancer
This study looks at why some HER2-positive breast cancer patients stop responding to the drug T-Dxd (trastuzumab deruxtecan). It aims to find out how resistance develops, which may help improve future treatments.
SeoulAges Any age - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05910398RecruitingPhase 3
Extending anti-HER2 treatment after breast cancer surgery
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
ShanghaiAges 18 years+ - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT05433753Recruiting
Study for leftover cancer DNA in HER2-positive early breast cancer
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
Chuo-ku, TokyoAges 20 years+ - NCT05314114Recruiting
Skipping underarm surgery for some breast cancers after chemotherapy
This trial studies whether it’s safe to skip removing underarm lymph nodes (axillary surgery) for people with certain breast cancers after they respond to “NACT,” a type of chemotherapy. It also uses planned breast-conserving surgery and whole-breast radiation to see if outcomes stay similar while reducing surgery-related side effects.
Beijing, Beijing MunicipalityAges 18–70 - NCT05464810RecruitingEarly Phase 1
Letrozole with or without a cholesterol drug for early breast cancer
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
Atlanta, GeorgiaAges 18 years+ - NCT04750122RecruitingPhase 1/Phase 2
Drug-screening guided treatment before surgery for HER2 breast cancer
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
Beijing, Beijing MunicipalityAges 18–75 - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 955 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.